Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion’s fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023.

The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13736225. A live webcast of the call can be accessed via the “Events and Presentations” section of the Reunion investor relations website here.

For those unable to attend the live call, a telephone replay will be available until Tuesday, February 28, 2023, at 11:59 p.m. ET. To access the replay, dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide the conference ID above. The webcast will be archived and available in the “Events and Presentations” section of the Reunion investor relations website approximately one hour after the conclusion of the live call.

About Reunion Neuroscience Inc.Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions. RE104 is protected under US Patent No. 11,292,765 issued on April 5, 2022 (priority June 30, 2020) with claims for composition of matter, methods of manufacturing, formulations and methods of use for a genus of hemi-ester tryptamines, including RE104, which could provide protection out to June 30, 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.Learn more at https://www.reunionneuro.com.

Follow us on LinkedIn, Twitter and Instagram.

To be added to the Reunion Neuroscience email list, please opt-in at https://investors.reunionneuro.com/resources/email-alerts.

Cautionary Note Regarding Forward-Looking InformationThis release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Reunion Neuroscience:Greg MayesPresident & CEO(215) [e-mail]

Media Contact:Shana Marino KCSA Strategic Communications(347) [e-mail]